Pharmaceutical

Lilly strikes deal with QurAlis for preclinical ALS candidate

QRL-204 is designed to restore UNC13A function, a gene identified as a risk factor in neurodegenerative diseases including ALS and dementia.

Jun 4, 2024 - 04:00
Lilly strikes deal with QurAlis for preclinical ALS candidate
QRL-204 is designed to restore UNC13A function, a gene identified as a risk factor in neurodegenerative diseases including ALS and dementia.
Read the original article

Tags:

Previous Article

ASCO 2024: Tagrisso approaches standard of Care status for NSCLC

Next Article

GRIT and Quangang announce IL-2 T-cell therapy partnership

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Risk adjusted net present value: What is the current va...

Nov 18, 2023

EU agencies back Covid-19 vaccine update ahead of autumn campaign

EU agencies back Covid-19 vaccine update ahead of autum...

Jun 7, 2023

Direct to consumer channels change patient-healthcare system relationship

Direct to consumer channels change patient-healthcare s...

May 19, 2024